NAD+ supplements (typically NR or NMN) raise cellular coenzyme levels, whilst retatrutide is an unlicensed investigational triple receptor agonist (GLP-1, GIP, glucagon) not yet approved by the MHRA or EMA for use in the UK
Manufacturers seeking to win in this space should consider how to address the following success factors: Determine whether to go broad or target a niche: Determine whether to go broad or target a niche: Going broad has been an effective strategy to date, but this may change as the market fractures
Liu X, Li W, Wang M, Liu N, Yang Q, He Y et al (2023) Inflammatory cell-inspired cascade nanozyme induces intracellular radical storm for enhanced anticancer therapy
Ultimately, each person needs to be their own advocate and work in partnership with their providers to decide whether GLP-1 treatment is the appropriate path forward for their eye and overall health.
Is the Sabra Hummus Snacker Actually Healthy
Semaglutide: Double-edged Sword with Risks and Benefits [PMID: 39902055] Laboratory literature summary: Semaglutide: Double-edged Sword with Risks and Benefits